GSK Aktie 119642297 / GB00BN7SWP63
15.06
CHF
-0.37
CHF
-2.37%
19.12.2024
BRX
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
GSK Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | GSK PLC Registered Shs | 4.00 | 0.58 | GBP |
| 2022 | GSK PLC Registered Shs | 4.26 | 0.61 | GBP |
| 2021 | GSK PLC Registered Shs | 4.98 | 1.00 | GBP |
| 2020 | GSK PLC Registered Shs | 5.96 | 1.00 | GBP |
| 2019 | GSK PLC Registered Shs | 4.50 | 1.00 | GBP |
| 2018 | GSK PLC Registered Shs | 5.36 | 1.00 | GBP |
| 2017 | GSK PLC Registered Shs | 6.05 | 1.00 | GBP |
| 2016 | GSK PLC Registered Shs | 5.12 | 1.00 | GBP |
| 2015 | GSK PLC Registered Shs | 5.83 | 1.00 | GBP |
| 2014 | GSK PLC Registered Shs | 5.81 | 1.00 | GBP |
Gewinn je Aktie- GSK
| 1.2 23 | 3.7 22 | 1.1 21 | 1.4 20 | 1.2 19 | 0.9 18 | 0.4 17 |
Umsatz je Aktie- GSK
| 7.4 23 | 7.2 22 | 8.4 21 | 8.5 20 | 8.4 19 | 7.8 18 | 7.6 17 |
KGV- GSK
| 11.9 23 | 3.9 22 | 18.3 21 | 11.6 20 | 18.9 19 | 20.2 18 | 42.1 17 |
GSK PLC Registered Shs: Die Aktie (in GBP)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 1.22 | 3.71 | 1.10 | 1.44 | 1.17 | 0.92 | 0.39 |
| Gewinn je Aktie unverwässert | 1.22 | 3.71 | 1.10 | 1.44 | 1.17 | 0.92 | 0.39 |
| Gewinn je Aktie verwässert | 1.20 | 3.66 | 1.08 | 1.43 | 1.16 | 0.91 | 0.39 |
| Dividende pro Aktie | 0.58 | 0.61 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Gesamtdividendenausschüttung in Mio. | 2’247.00 | 3’467.00 | 3’999.00 | 3’977.00 | 3’953.00 | 3’927.00 | 3’906.00 |
GSK PLC Registered Shs: Unternehmenskennzahlen (in GBP)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 7.38 | 7.18 | 8.42 | 8.46 | 8.41 | 7.75 | 7.64 |
| KGV (Jahresendkurs, EPS unverwässert) | 11.92 | 3.87 | 18.33 | 11.62 | 18.95 | 20.23 | 42.12 |
| KGV (Jahresendkurs, EPS verwässert) | 12.10 | 3.93 | 18.56 | 11.76 | 19.21 | 20.46 | 42.66 |
| KGV (Jahresendkurs) | 11.92 | 3.87 | 18.33 | 11.62 | 18.95 | 20.23 | 42.12 |
| Dividendenrendite Jahresende in % | 4.00 | 4.26 | 4.98 | 5.96 | 4.50 | 5.36 | 6.05 |
| Eigenkapitalquote in % | 21.68 | 16.79 | 26.98 | 25.87 | 23.03 | 6.32 | 6.19 |
| Fremdkapitalquote in % | 78.32 | 83.21 | 73.02 | 74.13 | 76.97 | 93.68 | 93.81 |
GSK PLC Registered Shs: GuV (in Mio. GBP)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 30’328.00 | 29’324.00 | 34’114.00 | 34’099.00 | 33’754.00 | 30’821.00 | 30’186.00 |
| Umsatzveränderung in % | 3.42 | -14.04 | 0.04 | 1.02 | 9.52 | 2.10 | 8.24 |
| Bruttoergebnis vom Umsatz | 21’252.00 | 19’462.00 | 22’304.00 | 23’123.00 | 22’885.00 | 20’925.00 | 20’086.00 |
| Bruttoergebnisveränderung in % | 9.20 | -12.74 | -3.54 | 1.04 | 9.37 | 4.18 | 8.94 |
| Operatives Ergebnis | 6’993.00 | 6’682.00 | 7’400.00 | 8’183.00 | 7’783.00 | 7’999.00 | 7’974.00 |
| Veränderung Operatives Ergebnis in % | 4.65 | -9.70 | -9.57 | 5.14 | -2.70 | 0.31 | 16.75 |
| Ergebnis vor Steuern | 6’069.00 | 5’630.00 | 5’409.00 | 6’935.00 | 6’147.00 | 4’769.00 | 3’512.00 |
| Veränderung Ergebnis vor Steuern in % | 7.80 | 4.09 | -22.00 | 12.82 | 28.89 | 35.79 | 81.59 |
| Ergebnis nach Steuer | 4’928.00 | 4’461.00 | 4’385.00 | 5’749.00 | 4’645.00 | 3’623.00 | 1’532.00 |
| Veränderung Ergebnis nach Steuer in % | 10.47 | 1.73 | -23.73 | 23.77 | 28.21 | 136.49 | 67.98 |
GSK PLC Registered Shs: Bilanz (in Mio. GBP)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 46’210 | 50’050 | 57’761 | 59’623 | 61’335 | 54’394 | 52’892 |
| Langzeit Gesamtverbindlichk. pro Aktie | 6.20 | 6.75 | 8.51 | 9.40 | 9.41 | 8.10 | 6.73 |
| Eigenkapital | 12’795 | 10’096 | 21’342 | 20’808 | 18’357 | 3’672 | 3’489 |
| Veränderung Eigenkapital in % | 25.94 | -29.60 | 3.21 | 27.90 | 161.58 | - | -106.05 |
| Bilanzsumme | 59’005 | 60’146 | 79’103 | 80’431 | 79’692 | 58’066 | 56’381 |
| Veränderung Bilanzsumme in % | -1.90 | -23.96 | -1.65 | 0.93 | 37.24 | 2.99 | -4.57 |
GSK PLC Registered Shs: Sonstige Angaben (in GBP)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 1.22 | 3.71 | 1.10 | 1.44 | 1.17 | 0.92 | 0.39 |
| Veränderung Gewinn je Aktie (unverwässert) in % | -67.26 | 239.07 | -24.14 | 23.05 | 27.35 | 134.80 | 67.02 |
| Gewinn je Aktie (verwässert) | 1.20 | 3.66 | 1.08 | 1.43 | 1.16 | 0.91 | 0.39 |
| Veränderung Gewinn je Aktie (verwässert) in % | -67.27 | 238.39 | -24.13 | 23.22 | 27.07 | 135.10 | 66.67 |
| Anzahl Mitarbeiter | 70’212 | 69’400 | 90’096 | 94’066 | 99’437 | 95’490 | 98’462 |
| Veränderung Anzahl Mitarbeiter in % | 1.17 | -22.97 | -4.22 | -5.40 | 4.13 | -3.02 | -0.84 |
GSK PLC Registered Shs Termine
| Unternehmen | Event | Datum |
|---|---|---|
| GSK PLC Registered Shs | Quartalszahlen | 05.02.2025 |
| GSK PLC Registered Shs | Quartalszahlen | 30.04.2025 |
| GSK PLC Registered Shs | Quartalszahlen | 23.07.2025 |
| GSK PLC Registered Shs | Quartalszahlen | 29.10.2025 |
| GSK PLC Registered Shs | Quartalszahlen | 11.02.2026 |
GSK PLC Registered Shs vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 30.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 31.07.2024 |
| Hauptversammlung | Annual General Meeting | 08.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 01.05.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 31.01.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 01.11.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 26.07.2023 |
| Hauptversammlung | Annual General Meeting | 03.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 26.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 01.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 02.11.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 27.07.2022 |
| Hauptversammlung | Annual General Meeting | 04.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 27.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 09.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 91.52 |
| Government Pension Fund - Global (The) | 2.36 |
| Dodge & Cox International Stock Fund | 1.61 |
| Vanguard Total International Stock Index Fund | 1.35 |
| GlaxoSmithKline Employee Trust | 0.95 |
| Vanguard Health Care Fund | 0.89 |
| Vanguard Developed Markets Index Fund | 0.83 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 98’462 | 95’490 | 99’437 | 94’066 | 90’096 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.31 | 0.32 | 0.34 | 0.36 | 0.38 |
Bilanz (in Mio. GBP) - Aktiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 15’907 | 16’927 | 19’491 | 20’247 | 18’674 |
| Summe Anlagevermögen | 40’474 | 41’139 | 60’201 | 60’184 | 60’429 |
| Summe Aktiva | 56’381 | 58’066 | 79’692 | 80’431 | 79’103 |
Bilanz (in Mio. GBP) - Passiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 52’892 | 54’394 | 61’335 | 59’623 | 57’761 |
| Summe Eigenkapital | 3’489 | 3’672 | 18’357 | 20’808 | 21’342 |
| Summe Passiva | 56’381 | 58’066 | 79’692 | 80’431 | 79’103 |
Adresse
| 79 New Oxford Street, WC1A 1DG London | |
| Telefon | +44 (20) 8047-5000 |
| URL | http://www.gsk.com |
Management
|
Amy Altshul
SVP-Legal, Research & Development |
|
Anita Kidgell
Senior Vice President-Corporate Strategy |
|
Anne C. Beal
Independent Non-Executive Director |
|
Anne-Marie Martin
Senior VP & Global Head-Experimental Medicine Unit |
|
Carlo Russo
Head-Development R&D Biopharm |
|
Charles A. Bancroft
Senior Independent Non-Executive Director |
|
Christopher Corsico
Senior Vice President-Development |
|
Claire Lund
Head-Environmental Sustainability |
|
David Simon Redfern
President-Corporate Development |
|
Diana Conrad
Chief People Officer |
|
Elizabeth McKee Anderson
Independent Non-Executive Director |
|
Emma N. Walmsley
Chief Executive Officer & Executive Director |
|
Frannie DeFranco
Director-Philadelphia Investor Relations |
|
Graham Rivers
Vice President & Financial Controller |
|
Hal V. Barron
Non-Independent Non-Executive Director |
|
Harry C. Dietz
Independent Non-Executive Director |
|
James Ford
Group General Counsel, Head-Legal & Compliance |
|
Jeannie T. Lee
Non-Executive Director |
|
Jesse L. Goodman
Independent Non-Executive Director |
|
Jonathan Richard Symonds
Non-Executive Chairman |
|
Julie Brown
Chief Financial Officer & Executive Director |
|
Luke Miels
Chief Commercial Officer |
|
María Cristina de Luna Basagoiti
General Manager-Spain |
|
Maya Martinez-Davis
President-US Pharmaceuticals |
|
Michael Elmore
Senior Vice President |
|
Mick John Readey
Investor Relations Contact |
|
Philip Thomson
President-Global Affairs |
|
Regis Jean-Pierre Simard
President-Global Supply Chain |
|
Shobie Ramakrishnan
Chief Digital & Technology Officer |
|
Sonya Ghobrial
Head-Consumer Healthcare Investor Relations |
|
Timothy Woodthorpe
Group Treasurer & Senior Vice President |
|
Tony Wood
Chief Scientific Officer |
|
Victoria A. Whyte
Secretary |
|
Vishal Sikka
Independent Non-Executive Director |
|
Wendy Becker
Non-Executive Director |